Welcome to our dedicated page for Atyr Pharma SEC filings (Ticker: ATYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing aTyr Pharma’s filings can feel like running a clinical trial of your own. Each 10-K is packed with tRNA-synthetase science, efzofitimod study data, and detailed cash-runway tables that stretch past a hundred pages. Skimming for pivotal trial milestones or anti-NRP2 pipeline costs is a challenge even for seasoned biotech analysts.
Stock Titan resolves that complexity. Our AI turns the aTyr Pharma annual report 10-K simplified goal into reality, highlighting safety findings, R&D spending, and key risk-factor wording in minutes. Need the latest aTyr Pharma quarterly earnings report 10-Q filing? We post it the moment it hits EDGAR and attach an AI summary that flags burn-rate shifts and partnership revenue. Real-time alerts surface aTyr Pharma Form 4 insider transactions so you can monitor executive stock activity before crucial read-outs. We also translate every aTyr Pharma 8-K material events explained notice into clear language, whether it’s interim data, financing, or board changes.
Investors come here to answer everyday questions: “Where are the aTyr Pharma insider trading Form 4 transactions?”, “What does the aTyr Pharma proxy statement executive compensation reveal about incentive alignment?”, or “How do I start understanding aTyr Pharma SEC documents with AI?” Alongside full-text filings, you’ll find:
- AI-powered summaries that explain clinical endpoints and financial pivots
- Form 4 dashboards showing aTyr Pharma executive stock transactions Form 4 in real-time
- Side-by-side aTyr Pharma earnings report filing analysis for quarter-over-quarter trends
- Automatic email or SMS alerts the moment a new document posts
Skip the page-count marathon. Our platform delivers every detail—clearly, quickly, and without the biotech jargon.
aTYR Pharma reported results from a 268-patient global Phase 3 study in pulmonary sarcoidosis comparing efzofitimod 3.0 mg/kg and 5.0 mg/kg versus placebo over 48 weeks with a protocol-guided steroid taper. The primary steroid-reduction endpoint showed mean daily oral corticosteroid (OCS) doses of 2.79 mg for 5.0 mg/kg efzofitimod versus 3.52 mg for placebo (p=0.3313), which was not statistically significant. Secondary measures showed a statistically significant improvement in KSQ-Lung score for 5.0 mg/kg (change 10.36 vs 6.19; p=0.0479) and a higher rate of complete steroid withdrawal with KSQ-Lung improvement (29.5% vs 14.4%; p=0.0199). Change in FVC was similar between groups (−1.81 vs −2.11; p=0.7875). Treatment was generally well tolerated at both doses.
FAQ
What is the current stock price of Atyr Pharma (ATYR)?
What is the market cap of Atyr Pharma (ATYR)?
